布地奈德联合地塞米松雾化吸入治疗急性咽喉炎的疗效观察

Efficacy of budesonide combined with dexamethasone atomization inhalation in the treatment of acute pharyngitis

目的 探讨对急性咽喉炎(AP)患者联合采用两种糖皮质激素类药物雾化治疗的临床效果。方法 将86例AP患者纳入本项研究,开展时间在2019年5月至2020年6月,采用随机排列的方式分为单一组和联合组,均采用雾化吸入的方式进行治疗,其中单一组43例患者选用药物地塞米松,联合组43例患者选用药物地塞米松和布地奈德,从临床症状消失时间、炎性因子水平和不良反应三方面对比两组间的疗效差异。结果 联合组咽痒、咽痛、咳嗽和声音嘶哑等临床症状消失时间均短于单一组(P<0.05)。联合组治疗前白细胞介素-6(IL-6)、C反应蛋白(CRP)和肿瘤坏死因子-α(TNF-α)水平与对照组无明显区别(P>0.05);联合组治疗后IL-6、CRP和TNF-α水平低于单一组(P<0.05)。两组不良反应发生率(18.60%和16.28%)对比无明显区别(P>0.05)。结论 两种糖皮质激素联合雾化吸入治疗AP患者可以在保障治疗安全性的同时,发挥更加显著的抗炎效果,临床价值显著。

Objective To investigate the clinical effect of atomization treatment of two glucocorticoids in patients with acute pharyngitis (AP).Methods 86 patients with AP were included in this study from May 2019 to June 2020.They were randomly divided into single group and combined group,which were treated by aerosol inhalation.43 patients in the single group were treated with dexamethasone and 43 patients in the combined group were treated with dexamethasone and budesonide The level of inflammatory factors and adverse reactions were compared between the two groups.Results The disappearance time of clinical symptoms such as pharyngeal itching,pharyngeal pain,cough and hoarseness in the combined group was shorter than that in the single group (P < 0.05).Interleukin-6 (IL-6),C-reactive protein (CRP) and tumor necrosis factor before treatment in the combined group-α(TNF-α) There was no significant difference between the control group and the control group (P > 0.05);IL-6,CRP and TNF in the combined group after treatment-α The level was lower than that in the single group (P < 0.05).There was no significant difference in the incidence of adverse reactions between the two groups (18.60% and 16.28%) (P > 0.05).Conclusion Two kinds of glucocorticoids combined with aerosol inhalation in the treatment of AP patients can not only ensure the safety of treatment,but also play a more significant anti-inflammatory effect,with significant clinical value.